Shanghai Escugen Biotechnology Co., Ltd

This study is testing whether a new antibody treatment called ESG206 can safely reduce disease activity in people with primary Sjögren's syndrome. The trial will involve 40 adults with active disease who will receive either the treatment or a placebo. Researchers will measure cha…